TMO - Earnings call transcript Q4 2019 | Thermo Fisher Scientific Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2019 Fourth Quarter Conference Call. [Operator Instructions]. I would now like to introduce our moderator for the call, Mr. Kenneth Apicerno, Vice President, Investor Relations. Mr. call. the begin please Apicerno,

Kenneth Apicerno

Good morning us. for thank you joining and

and Marc me President Stephen On President with is Williamson, Financial Casper, Vice and the call Officer; today our Officer. Executive and Senior Chief Chief

expectations of this heading earnings XXXX. on Investors available the A our the archived is heading copy note will thermofisher.com, Presentations and and release our the call live under of Section webcast website Please Investors and Financial our being the until XXXX be Section Webcasts website future of Results. fourth quarter under is in February press X, of the

Before including report purposes the under we future available results a let briefly those heading September the under these as important under Factors, provisions of company's constitute Securities expectations, we that Harbor from indicated cover our on prospects begin, Safe Various Reform also Actual SEC the Harbor statements remarks the statement. and XXXX. the quarter Private file the Investor Exchange Act caption is Form of which XX, section me Securities for on company's of and Commission, make ended XXXX the with Risk may the plans for about Litigation materially statements result may website the differ forward-looking and Safe in discussed on XX-Q is in of our various factors, filings. quarterly the forward-looking

subsequent these if at estimates forward-looking forward-looking on today. our point obligation we update we the should statements do disclaim some any as to of representing you as not change. may our to elect date views even While any to specifically statements in Therefore rely so future,

under financial with Principles to we'll the our in measures section quarter call, to measures directly Accepted most non-GAAP and reconciliation heading comparable be measures website or is the of also and Investors in Accounting this Generally of financial Information. XXXX in of release prepared certain expectations press earnings these A during our available the fourth Also GAAP referring the not GAAP. future accordance Financial

now I'll Marc. that, to with the turn over call So

Marc Casper

Thank and year for I'm goals year you Thank and you, that the for finished exceeded us XXXX call. QX our XXXX. pleased our Ken. Good today to we morning strong for report everyone. end joining

All capital saw our positioned an perspective, this financials revenue well the our good all, to strategic significant new making at we quarter proposition. release, And acquisitions our and begin shareholders cover be I'll highlights capabilities returning press my very year financial From many was hit lens, continued but as some exciting to a and unique high you our in delivered later added as to of first the create new value. in capital, and I'll we company. growth. our remarks, in excellent products we even the launched customer and it of excellent From strengthen Thermo an We've the decade earnings new for stronger from stewards to year. Fisher level. value

X% to billion to X% in to XX.X%. in revenue operating adjusted Starting billion. points with X% in operating XX growth expended quarter. the also was QX Adjusted QX $X.XX the our Organic year-over-year our increased margin increased income basis quarter, $X.XX and

increase to growth strong with Finally, we achieved share. the in adjusted quarter EPS X% per $X.XX

Organic by operating year. year performance an we XX adjusted Turning expanded of share. revenue to X% increased points billion another per We margin to $XX.XX in the with X% excellent XXXX, operating the delivered XX% billion. $X.XX basis increase in XX.X% earnings adjusted to by Adjusted year, growth increased to results for and for EPS revenue was our income we X% full to $XX.XX XXXX. in

store our performance of our power the PPI know, Business System. is you As by fueled

– world. not aspects the that creates it of company growth, and our This use this not better strong but even for our the also a to colleagues all experience colleagues make us improve to helps company we leads continuously around across only great Our is our how XX,XXX earnings and work. customers

give end businesses color year. delivering by market excellent on now quarter the performance and end and again customers. we the broad-based some the you me these across saw strength for pharma biotech, QX. during performance in our Starting Let growth XX% had market with our We serving

which we depth Our my later in advantage competitive to and to us gain unique capabilities our continue a remarks. clear share, of offering I'll strengthen gives cover

position in to we clinical healthcare In we double-digit in in and customers care, year. in the channel grew biotech quarter market immunodiagnostics, for year. market saw and this growth the end health strong full this leading growth mid-single market and the businesses serving QX the both led Our diagnostics for our in pharma in digits and and end diagnostics

This Turn business, was microscopy electron in into digits consistent predominantly compared with our growth mid-single industrial by in what end in declined this year. QX last driven and QX. a we QX we the applied, market the in delivered in growth saw dynamic with double-digit

and quarter In For full in the for full government, low-single and in grew year industrial the the and year. low-single grew academic we digits the applied digits. during the

comment This strong release funds some coupled the of purchases we year in Finally, of let In performance lens. on briefly customers. driven capital slower ago from low-single me by QX, with grew very was in geographic in quarter, digits. for China our our the comparisons a a by

Europe our Our of company. for very to total performance strength speaks strong, excellent the growth competitive the position. and in North portfolio That America revenue our global driving was and

another well To performance, overall excellent to conditions team's year. our good be sum up continue market to and achieve our executed

deliver effectively to to some use framework recap transition strategy the growth to it as a very highlights good the year. and the our to our a value for That's and proposition strong customer growth. I'll We of quarter a continue leverage unique

to momentum three and to share. strategy the Fisher all Thermo customers We across continued position of elements strong in market with best our our our win gain put

an and all every our of year was strategy, businesses. of focused highlight few this Starting technology for a just it high-impact I exciting products launched our We exceptional with across the quarter will morning. innovation. first new pillar

at big our you'll bar In quality we demand which with instruments, XXX new strengthened it raised biology system launched for significantly for Metrios mass applications. the the in introduction Exploris these we systems, of and protein electron the uses year. for new We very customers. the GX to see analysis. industrial Krios ensuring pleased and introduced analytical efficiency Orbitrap ASMS, the And for our critical products. during This microscopy customer collection us with automate Scientific business, measurement new generation recall instrument In was Tribrid our new our QX, of Eclipse Thermo learning for strong leadership structural in AX instruments. machine generation to our and spec of the year We're a data,

segment, ImmunoCAP transplant our we to extended assets family allergy of diagnostics particularly In menu specialty new our our business the added number LABScreen tests. year, expand during in of QX. our a diagnostics, In we continued where of immunodiagnostics we in reagents

reagents Our number new directors the single lab help greatly ExPlex that HLA can rejection identify to expand antibodies the risk characterize of in organ antigen transplantations. of

minimal eight Pro introduced the our QX, and a by we life Flex the QuantStudio to requiring Torrent our highlighted range cap in to system, our Fluorometer, extend generation of system sciences Qubit and single results. accurate the day bio-production, off products genetic measure amounts launched And is sciences sample for In in reproducible strengthen This excellent simultaneously samples a and Turn an highly we to Genexus year, and sequencing the changer, real-time designed solutions to fully offering and which X we X biosciences segment, next up a results launched systems. to real with platform. is analysis. game automated QX Ion delivering PCR of to

oncology-focused real and NGS and is milestone to to teams in for been our significant culture. to for continued a a ultimately our I'm of This a We've local the NGS great goal with element have make progress has key of our innovation bring settings. that customers. difference hospital always makes our passion Genexus proud strategy our

momentum So continuing and XXXX. in regard year forward we that clearly to look fantastic another our in

in included China growth XX% pillar strategy, emerging these regions great to the we And in growth our another across strong and markets with had scale key high growth. XXXX. in our second that performance year Turning leveraging of

government priorities demands for we food build drugs, environment our on to biologic a and leading customer solve continue help cleaner technologies with industry the meet are safer the to provide, scale China forward, Looking them aligned to challenges. supplies. in And we these

meet highlighted growing new You demand. that clinical to developments will operations many expansion our of during trials the recall China in including we year, the

in help it To new world. industry development scale around showcases how well positioned has and an that is for how our I market expertise our This During exceptional critical by to QX pharma workflows The we sum of rapidly leveraging expanding Shanghai. and from a a out distinct we unique up, customers analytical across specialized our accelerate created experience came and solution the therapeutics. and a plays strategy our our growth. markets advantage center away processes opened allows in the there. excitement my are that we've visit in is China and China with to customers leading deliver Thermal emerging and to center the support incredible there us high-growth customer that Fisher quarter, in their for novel to biotech biotechnology that

their build South and on Singapore, help As the food in you customers continue during sciences, advance applications. India, that also in work life heard to our and year, biopharma safety we our Korea, capabilities

because new and for The proposition. strongest these customer for meet existing biotech for offerings pharma to it's we innovation help is enhance continue our been talking their productivity. And bringing third a partner the be to growth value capabilities of our We've our of customers about lot pillar together to adding our and a example strategy we're and goals our customers. great ones how it

We the them We the a resonates introducing to of formula customers for our our revenue making access channel it scale through and across to CDMO and to the extensive support market And synergies a proven relevant this drives portfolio. and these do service also product medicine. capabilities, which discovery our and have pharma research customer leveraging have it virgin to way by a continuing strengthen biotech. molecule all from of safety technologies, can our to commercial expand we combination serving new a smaller large continuing offering we from our

again outlook. able once that's and that over has been our was successfully a two our a we We pharma the were acquisitions. a since covered a into combination with high-single bright growing been in bolt-on high-level the but already We've of year, a services a organic mid-single digit development strategic lot delivered is investments approach the well at and in customers. acquired the during double pharma digits of business we've working integration. a grower formula XXXX It's our we and turn biotech with This years completed to growth digit and Patheon very

Organically strengthen new capacity sterile position. to our to we've also customer network expand including capabilities demand, meet fill/finish our production We services. to global and continued biologics acquired our for We've manufacturing facility our added of acquisition the therapy and in Ireland Brammer market new capabilities growth acquired that increased the API high in the Bio. significantly from we with gene we GSK

grand vector December, I early new In in Massachusetts. the opening facility viral of Lexington, our attended

customers about I'm extremely patients strong opportunities is really team well. Our potential. super we about Bio and to has integration with the therapies is this innovative bring diseases. performance of have gone there Brammer now our excited The rare to excited new Business help

we pharma continue excellent share. key clear it's value So serving a momentum proposition biotech competitive and is our that customers, our for advantage to gain and us is

deployment, track in our shareholders execute capital to good in have strategy you value and XXXX. of to stewards for creating now capital successfully being our know, Turning continue here by great as a record we we

we $X.X First bolt-on billion acquisitions. deployed on strategic

a debt will that that refinanced and to savings for to shareholders of continue generate million share you our in billion buybacks we capital announced QX return $X.X $X.X Last, that in us. $XX Second, total recall annually we for in our billion of dividends. we and

sheet So it and was as capital perspective a a from well. year deployment great balance

cover to mission, a embodied company guidance customers have healthier, to life is to Let doing in in to cleaner, we to and happens STEM colleagues a our through and but ways, better. connect profile Stephen me our that relates our make cover which one our quickly always a but let commitment our guidance, We've our environmental and we education but This so ESG And company here, to before our We make sustainability highlights. to that our raise day, mission that's on communities dwell to I'm programs of even safer. not including every that governance our and and turn way. into also social assumptions focused will priorities. me impact. can the I be that's still robust of and factor done environmental, doing customers, to on our work initiatives, make direct are proud much number the only world teams and the the the enable right our been more continue bring business last year highlight from revenue earnings the

our would to This EPS of revenue to growth billion result of to in growth XXXX we X% X%. billion year-over-year. We're guidance XX% for and revenue XXXX, which initiating in between terms $XX. of the range In X% $XX.XX expect to to adjusted deliver guidance, $XX.XX in XX. $XX.XX will lead reported

delivering to to make customers significant Business value puts and company year stronger. for shareholders, revenue and We're my strong our Before over you earnings begin I to position exceptional as leave call enhance our very consistently we've and for track with proposition unique our customers in System the our even another in key we continued continuing the performance by year. with takeaways growth a to strong an XXXX. extended for our hand I'll value excellent achieved experience Stephen, of decade. which our the And We've record PPI using create our us

Stephen With call Williamson. now that, over CFO, hand I'll the our to Stephen?

Stephen Williamson

XXXX Marc our results fourth segments Then a full our for begin morning and everyone. year of quarter an four color of company. I'll on conclude a review Thanks, with some total our and and provide the good with detailed initial overview guidance. I'll

it'd to our helpful versus a out call. of thought the provide of the our performance, how of played I time I get earnings financial the details fourth view high-level be quarter the into Before expectations last

the pull-through and favorable was along growth midpoint We EPS FX. results ahead organic the and X% than of our As guidance, press $X.XX to reflecting you adjusted we previous line. year saw release, with top in bottom a the finish incremental, our of volume delivered guidance on had prior strong our and delivered higher both good below-the-line

in performance strong XXXX organic X% us financial year in in full deliver earnings share, XXXX. QX per adjusted Our growth for XX% to enabled the excellent growth so results and

with me on performance, you let our color more some earnings give results. the Now starting

grew EPS and You $X.XX. release by on our adjusted press saw we QX X% to

year, GAAP the versus adjusted year up EPS $XX.XX XXXX and $X.XX full with QX full was up $X.XX GAAP the versus For EPS up was the XX% year in quarter XXXX. XX% EPS from year. XX% last prior

our components organic of and line, divestitures grew the X% X%. and The top revenue reported included approximately QX the approximately QX. recorded On exchange year-over-year net revenue our a of increase from headwind QX growth, in of X% acquisitions foreign X% growth

For increased the contribution and divestitures the impact from X% organic includes growth positive reported of foreign X% exchange. revenue X% full net from X% a This year or and acquisitions a year-over-year. headwind XXXX, from

single-digits, the the rest in and to Asia-Pacific growing grew which quarter. Turning grew the growth Europe geography single-digits, mid-single our during in North world low grew also mid-single-digits. single-digits grew by in in China America the including the the the high digits, low in of

both single-digits. grew of North grew mid-single the in and digits, in the full world and Asia-Pacific single-digits, Europe the high rest grew the year, the in For mix America

strategic Anatomical to and half of was was Pathology points by XX future growth. the business. operational divestiture by good guidance. operating from of than Turning This QX we'd investments, assumed acquisitions performance, increased and partially saw driven adjusted up and Business points was QX income to our of last and incremental were Half the offset the adjusted mix fuel last by X%, lower basis operating of basis our expansion impact XX.X%, other volume productivity System margin the in year. in FX investments XX strong our PPI leverage. We QX business margin that

increased operating operating just full by points productivity acquisitions than year impact through and adjusted XX.X%, the and with mix strong is which got X%. We've XX For basis Adjusted margin partially divestiture. income higher investments, of business strategic XXXX. offset the and pull volume

revenue, adjusted earnings XX headwind on a X% X% adjusted year operating at points on per margins share. For was FX the on and full basis

and a income operating points headwind was year-over-year the on approximately of in QX million Anatomical operating and on the adjusted a XXXX $XXX $X.XX business of As at of dilutive margin. adjusted our XX divestiture basis revenue, Pathology reminder, end $XX million on

the from P&L, quarter in came basis of in the of the prior to at XX company on Moving details margin points the QX XX.X%, down gross the acquisitions total adjusted basis XX was the points this year; impact of of divestiture. and

XXXX. XX.X%, from XX For down adjusted the was gross full points year margin basis

year, investments strong volume impact quarter of For divestiture. and full more strategic acquisitions offset mix, and pull both the than business and through by productivity and the the were

an the in expense lower versus of points R&D in revenue, was last of QX quarter Total revenue, SG&A points came of XXXX. at XX basis XX.XX% X.X% year. improvement QX than Adjusted XX basis

points For the to lower SG&A sales, R&D X.X%. was an prior full for XX.X%, the full-year as of revenue the XX than the year basis XXXX. points percent full was of expense our was improvement of adjusted manufacturing a R&D compared year. year basis X.X% XX

at below-the-line and expense refinancing year. with from of expense million, expense decrease $XX reduction net Looking last actions. a the our debt down $XX interest was driven in QX million[ph] XXXX. the Net for by reduction for million net year full results interest was quarter, The interest our from $XX million, $XXX

higher Adjusted basis than quarter the rate points a foreign other and QX XXXX. net exchange. due to XX in in QX was expense versus quarter the in XX.X%, $XX tax income XXXX, income of was million, Adjusted non-operating changes down primarily

points previous of reflecting planning than reform XXXX XX% impact tax and tax adjusted guidance basis tax our with with the rate full-year continued primarily initiative. in U.S. beneficial line Our the full-year is lower XX

our of both year, million and Average the diluted for $XXX million QX $XXX XXXX to shares repurchased were we call, QX in full the with the shares of guidance. repurchases in on $XXX line billion. million total that prior QX in mentioned bring $X.X I early As

cash to flow Turning balance the on sheet.

free For the billion continuing $X.X $XXX after million. year net capital with cash cash from flow and deducting operations billion and was full flow approximately $X of expenditures

During also buy as to million share $X.X backs to significant And XXXX capital per Mark with we of continued billion mentioned, successfully shareholders $XXX return through in dividends. acquisitions. $X.X capital strategic deployed billion we

the $XX.X billion total cash approximately billion in of year ended and with We debt. $X.X

by debt quarter. end refinancing our QX total $XXX in debt driven completion the began activities, of up of prior the million was Our from the which

with of X.X adjusted our Our leverage ratio line at debt to year expectations. the gross the times EBITDA with end in

my performance, quarter was total XX from or XX.X% up points continued up company adjusted in XX very comments points our as Wrapping last generate basis basis ROIC we to in strong return. last and year QX

in Not on the In the for color solutions. organic X%. was revenue led and growth segments revenue quarter business provide QX four genetic year. and quarter you with bio-production, bio-sciences this full with of to strong increased and segments the growth reported Started performance science sciences. this by see In continued we segment X% some our life the in

full For increased income up year-over-year. Life the reported XX growth adjusted XX.X% in increased revenue points organic Solutions adjusted revenue year XX%; Science basis operating margin was with operating X% XX% and and QX

quarter we very strategic strong drove is investment. pool by mix which partially the and In productivity volume business through and offset

points For the income increased XX.X% was adjusted adjusted XX% margin and XXX full and basis operating increased operating year XXXX, XXXX over with

XXXX, segment, have organic comps particularly our growth decreased very in businesses by In the all in business. in that the the declined Analytical segment given revenue microscopy strong Growth QX year-over-year electron X% we QX in and delivered organic XX% reported revenue X%. Instruments

this China addition, businesses purchases in growth slower for the In in QX of funds for the release capital segment. impacted

productivity, saw was we and segment down QX was X% operating strong year in offset For year-over-year. income adjusted business mix, very X%, operating decreased investments volume XX report the XX strategic by points than basis X%. revenue quarter, more year. was increased year, higher margin the basis XX.X%, prior adjusted than the operating points full the which XX%, was and the income instruments For growth In adjusted organic analytical in full

Diagnostics Turning Segment. to Specialty the

over which the segment strong diagnostics revenue organic our Pathology total reminder decline in is growth led business, X%. at In growth in immunodiagnostics channel. X% a clinical the divested market by and we included this continued with revenue QX. healthcare of end this that saw As was segment businesses We previously the strong Anatomical our QX growth

in flat, points of full we with was Adjusted mix. impact year, falling For operating business the the prior X% and the reported in decreased impact and strong growth margin quarter, the than the the XX.X% In saw revenue and X%. QX, leverage, the and was due divestiture income more basis to strategic was year operating productivity down by however offset and adjusted organic divestiture. this investments XX of

XXXX, adjusted operating year basis XX full representing income operating contracting adjusted the divestiture with XX declined with For points. basis a year-over-year margin X%, points XX%,

In Services quarter our revenue in Laboratory was Products research and by the of channel. reported the within across led strong all market and business saw Finally, the organic increased businesses the the segments revenue growth segment and QX pharma we X%, X%. services growth safety

XX.X% investments. For grew by and in operating This than and which was X%. operating strategic full In the partially organic saw and was leverage favorable for we strong business higher from productivity, both the by contributions Adjusted very basis margin year XX% increased was the mix. revenue prior XX quarter points. volume acquisitions the offset income year segment adjusted reported

XX.X%, to full flat margin was For adjusted XXXX. year operating the

of adjusted would With a guidance Mark result details which And mentioned earlier, X% XXXX. XX% the over to XXXX $XX.XX that $XX.XX like review to growth we're initial in as our of I’d range XXXX EPS initiating guidance. to

range XXXX. billion, X% guidance to result to revenue, billion growth terms of is $XX.XX In our in would of over which reporter $XX.XX X%

initial X% the guidance year. assumes XXXX organic growth for revenue Our for

adjusted EPS it's FX or to extent in lesser $XXX and QX QX. in of $X.XX in X.X% we're XXXX assuming With or largely a approximately regards year-over-year that a revenue and million headwind X.X% of of to

million completed growth reported business, the contribute revenue in which respectively. XXXX. of dilution and $XXX million We $XX of of $X.XX reflects operating Anatomical our acquisitions expect XXXX and income we revenue in the $XXX assuming from sale million approximately We're to headwinds the will Pathology that

business. million re-investment to made into margin, of adjusted to back decision This operating basis adjusted operating margins the year’s debt $XX Turning XXXX last points. XX the by impacts reinvest refinancing we

XXXX In have margin of Diagnostics points which business, from to expect for PCT our Specialty our key decision renew in of part my to we addition, is impact commercial about contracts basis XX test segment.

most royalty rate our some revenue with With franchise successfully partners. long-term operating revenue of creates extensive exchange PCT million concessions of test with this a XXXX negotiated extensions but commercial years adjusted we In for for about contract in many this stream income, and successful highly $XX headwind of return, to come.

Factoring in the PPI and operating benefits margins and impact adjusted strong in System, growth on of organic strong divisions from approximately in expand we adjusted of points these XX of XXXX basis the XX.X%. to continued margins resulting two productivity through Business the operating fall by volume our expect

line, net We're approximately XXXX adjusted million. in $XX is level. $XXX the year below debt lower debt expect and million be net refinancing past lower about to other than This expense XXXX Moving the assuming the and we interest reflects will income million. average completed $XXX we this be activity

the tax by The rate continued of reform. adjusted We from improvements XXXX. in our with driven primarily to the rate U.S. realization XXXX XX% expect associated income is benefits in tax be XX.X%

in our capability range This growth. bioproduction represents over earnings billion. We're $X.XX businesses. strong driven is to be billion is net expected capacity The cash flow capital increase investment of in expansions pharmacy by billion our XXXX. and to over $XXX the approximately million of approximately $X XXXX services increased driven XXXX, expenditures $X.X and primarily by Free assuming an in expected

throughout $X.X capital we which billion share buybacks of our deployments, year. XXXX completed includes terms total In guidance a the be of assume will in of

through between million full-year shares. diluted We're also XXX to assuming capital that return shareholders count approximately year estimate will and share be We million we'll average this $XXX dividends. XXX of

Our the noting guidance It early our not impact the is too we It's potential customers on assume from to any guidance can acquisitions impact. help everything any colleagues address our fully also We're worth include outbreak. focused the to doing and or does Coronavirus divestitures. situation. does gauge future our that not

for quarterly on phasing touch consider. year. to several wanted There are I the to Finally, factors

this days First, have that and note less in extra day year. in we one QX QX two

For and due to organic than growth the higher we And analytical impact instruments couple expect same reasons. prior to of the full-year comps, be than expect a the the year the the QX points full we lower in standpoint, segments. year particularly for day's QX be to

to and phasing year over to approximately of and of year to and year net the as expect expected From by the be for basis lower than we standpoint, driven the for a neutral in and adjusted XX EPS in an QX the Due in equal. expect be are the the points whole. adjusted revenue QX we organic the of QX, just stamp diluted This timing margins QX phasing to and about is approximately full points year XXXX rest in QX the of are QX divestitures investments accretive margin to of acquisitions. operating XXXX. revenue XX% be income Acquisitions be XX%. basis and XX our QX

excellent adjusted high growth X% our X% to to So guidance of assumes to at year, a organic EPS record. revenue financial level track growth, XX% performance start the continuation

to As and look updating through go you best as forward strive deliver year. always, we the the to progress our I possible results on we'll

call give Ken. that, With I the to back over

Kenneth Apicerno

open ready it Thanks for up to Operator, Q&A. Stephen. we're

Operator

question you. comes Thank And the today Peterson Morgan. [Operator Instructions] of our first with JP from line Tycho

Your line is open.

Tycho Peterson

Marc, to in performance want the Analytical Instruments start morning. good Hey, business. with I

but last those semis China quarter? dollars Life there's could anything it FDI? up weighed was talk if Can versus of the in quarter, to below that notable hundred there pacing? had come maybe quarter? to of the about quarter-over-quarter with there's It that maybe you difficult of talk in and looks release a else Sciences a dynamics of like talked deceleration the Did anything AI and late a lagging tracking funds. slower down couple million FDI’s anything You suit. two comp much you Is You in How terms here.

Marc Casper

for question. thanks Tycho, Yes. the

In terms as in we analytical of said you growth instruments, the had XX% prior year. the

happened our late that on little that has customers was performance in actually and capital as you into slower below electron a comparisons, we were release our specific the were XXXX. a first think expectations equipment about bit quarter have said going in XXXX the going When had, of China second from that as expectations half in to really a very business that So of very funds we and strong headwind a in quarter market. the with the high-end microscopy we strong

played we much knew expected? challenging there out have we comparisons and we that So as pretty

Tycho Peterson

about factoring follow-up on maybe you just talk of a the any on the I And guys Can business? expecting then the the in some release is And on we diagnostics about on just you're of and impact, for are you the funds? an for ketchup and about China takes, side, other gives for gives positive Coronavirus And opportunity obviously maybe guess there China. is talk not the you the Coronavirus think yearend. takes but

Marc Casper

Yes.

China in I versus the QX, me we the were things from continues Analytical and the a right, to in continue would in customers look our for low-single-digit the fourth expectations expecting which is really XX% highlighted as in Instruments Feedback in let which that growth contact, – year very came be We I on China growth comparisons, a have quarter. business I just strong is to we perspective, I based in the we cover So mid-single-digit that mid-single-digit And positive. our back in the with China. we position country. when strengthen China we From strategic liked had on always to year, and keep in growth.

the And equipment. slower consumer of of as strong capital businesses release the saw of quarters, when you very is businesses the remainder majority growth play really service portfolio. high-end in and exactly three obviously various the the enough, the Interestingly or the was business, actually out rest the of the which capital previous across business, driver the look at our of we that all

seems other. the on decisions or take and into one it forecast large so So made Thanks, like our some isn't government the and equipment to to hold capital funds purchases baked our that's – Coronaviruses way very there Tycho.

Tycho Peterson

thank Okay, you.

Operator

line the Jack from comes Meehan question next Barclays. of Our with

open. Your line is

Jack Meehan

microscopy digits weighing more Thank on quarter. end the bit you. little that. wanted on so the applied electron to industrial a I down probe mid-single morning. markets, Obviously, in and Good

if the And does the Was guidance that, in for that Just some as year-over-year? what end that seasonality also the I'm you're terms excluded about of an macro. for talking XXXX? – excluding capital curious you you're assume weaker of seeing market there, what

Marc Casper

Jack. So,

low And same then the industrial to day-to-day year, in flip had the begin in we comparisons assuming and We rate growth up really, – substantially the and phasing, the run the for in the for exactly challenging is XXXX. sort comparisons And We guidance plays of then QA/QC are. single business terms of the changing always applied. see industrial we in saw year first year pockets at look it's our conditions a I look year little some has industrial in the the assumption how grew industrial And just accelerating applied applied, last applications. as you'll strength. eased on, really year. of markets As start very applied. strength and there's digits challenging of the is what's really bit single-digit applied to so this same – And thing goes right? more the the have market that's as softer we comparisons a as some and in and at And you year. When half out. strong low year is The happening only therefore,

strength, purchases comparison a equipment capital in the larger some saw science but difficult had You material and applications. semiconductor primarily

Jack Meehan

Great.

had follow-up. how did tough that AI do a gains you mass all feel chromatography, just I competitive versus Okay. about provide And but the on and you that how the color Stephen then Or could from more was a some the I just hoping also in think, within was comp? comp, know as mentioned, businesses environment? the grow? feel share negative quarter And spec – you

Marc Casper

Yes. in three business quarter lines of in because analysis segment the mass businesses all Instruments, Jack, analysis. was materials chemical comparisons. Analytical so and have and declined as terms three our a very business within structural our below Instruments reminder, average All the had chroma and strong spec three Analytical we

how year. the three Thank of Our feel electron analysis above chemical I during was and in the businesses. average and structural was our Jack. below the full you for segment it terms the and segment of chromatography average spec shared at strongest business the and the performance spectrometry about And we mass mass good the analysis chroma you, of year. or look when year, the microscopy full performed for performed course materials the

Jack Meehan

Thank you.

Operator

line De comes question Derik the of next of Our from America. Bruin from Bank

line open. is Your

Derik De Bruin

good morning. Hey,

Marc Casper

Good morning, Derik.

Derik De Bruin

been deployment GSK Hey, and deal profile? of Brammer the on that be with margin you're on deal, that I'm done in. because the I a the the deals growth could recently, just at to on you And that step I opportunity further this? margin margins on and balance look just in have putting sense pacing add, sort trying GSK Marc, Brammer mean, get in point add a can higher I'm some potentially basis the what that margins. trying a of into you've lot the you stuff is this looking investment talk this pressure other demands, of assets some to – and margin be like a conversation little time? you get will at dilutive and the bit capital this on about there – And bonds of mean new would guess, like to of sense when to sort sort of go-forward opportunity a lower capital trying more you're I

Marc Casper

Yes, Derik. question. Thanks the for

focus at are the generally margins things how And done first try look So been from are and what was we actually just thing have is M&A that do that from way. We and is. years, is business as on day What the When are M&A the we perspective what right? many So sometimes answer one. margin that starting short an accretive done right to headwinds. we've term operating we with to profiles return right? and can Meaning, dilutive, we have owner, about ones the I what the know, think will you over we've don't this M&A. about we the – you'll

with increases that When three-year look the we margin say, up margin points XXXX. the our And balance model to have then whatever but Analyst savings, conscious the the care to roughly our workforce in health team sheet tailwinds. we QX, the of which set excellent of interesting franchise margins to and XX to had it, good they're And give a company. was that second assumed identify in is adjusted carve want refinance possible "Here's I was business same Analyst I prospects. Day was laid to Sometimes, And right? capital What always the expansion and very extension of the laid we conscious effects wage increases course expansion out economic tax trading forth. good Stephen great and the margin some we on manage very everything the going out of details. was strong on with the the made relative base to we not out the we've when cost in rate view. end And I guidance, the a mitigate do a feel way. choice, part reinvest and and EPS the those our When in had in our the of the at decade-long explain in we for we of outlook, of during before acquisition Part tax the are we the PCT assumptions planning have always core, along some reinvest for explained made we short-term opportunities, just talent growth that, try to the basis expansion, decision at we to that assumptions still basically U.S. a actually some about opportunity at decisions, growth of come deliver made deal market had of hourly of our XX additional is a deployment the growth for – EPS to at basis is best the points the and to in we because look additional forward." because decision funds Day, XX EPS the to out growth, on average population. very so able it over deliver And what because the our relationships, acquisitions And

beyond. just we're or so where the slower then I other, margin would XXXX was would that And the rate taking of the things EPS, this articulated. way in be year. just based a and expect right no I margins factor model expansion other back on that And one

Stephen Williamson

basis thing and much about acquisition – margins the just Derik, one line profile acquisitions divestiture gross the points is in the our margin. margin the and XX and impact – is the income. clarify And much, impact the That on smaller divestiture our to bottom comment the divestitures of really of adjusted on operating gross of QX caused the than terms dynamic there. the kind what's It's

Derik De Bruin

quarterly XXXX the all about three think gross we on be should over how so the And margin a since target that to basis? place for seems

Stephen Williamson

Yes.

from think depend probably is for margins of be to in. will But basis good the revenues XX roughly about actual leverage next that gross year, a margin comes think it most year those selling will of on mix obviously, flat coming So point I points. expansion the of the SG&A, and

Derik De Bruin

got another follow-up. Okay. Good. I

Ion NGS I about thinking it's Thermo. we've really So been thought hadn't Torrent. time – I've thought really since a and long about about

You closed the Life deal.

investing would competitors' how given are space? And very I see mean, more there sort And for? I'm and the going in that that so shaking terms you to and in talk your are that out in interested some guess, where curious that. there? footprint dynamic of kicked of research of you've like be been your you the is clinical can doing into versus getting market more out of there space about sidelines. assets you're I just you competitive being large plan what sort of the sort general more

Marc Casper

Yes.

for thanks question. the Derik, So

business. since outstanding. can November read about opposed we well really a and NGS sending And the being is five really incredible change we with have the is that in AMP XXXX to customer and the focused benefit which platform, think market. focused sample out the treat or way the as because how And we is of have in stream launched on you interest very for market a it Genexus have result you've getting at three you received years sample patient, can our then seen, Genexus answer, the an ultimately And later steady all a impact sequence the decision your launches work last market, to our about. to have product is terms come so, information. based an make and the of on That's And which oncologist of the researchers with use uses the ease to what of technology a day weeks And into very two over next completed. DNA patients. you a relative oncology been NGS, In alternatives a maximizing can the on clinical get less and a on you

and extending of terms applications markets, outstanding, where other right NGS and our focus. platform on focus other within some to is where kept we – that's is oncology In our now really our

Derik De Bruin

of sort can you sort of And does LabCorp give signed wondering, just I'm sort agreement any you some an in could us with market. the idea – NGS idea LabCorp in And on volume of that what space? – the

Marc Casper

was network. their exciting within roughly to six they to that I And across their wanted runs super been their that excitement number launch of have NGS announce network. thought the a using actually about weeks I and obviously of to huge Genexus world that it mean, tests LabCorp us

into, really think I going companies. both great a obviously, nice it's not And the but for get specifics, we're So win that's to opportunity. a

Derik De Bruin

client. can Chinese that's in One what squeeze one obviously going in settings if the there. more And a are not Thermo's people is investor know from hospital I wants to since – exposure

breaks Just regard your how China any idea of sort that business in diagnostics? in on which down on

Marc Casper

Yes.

In care it the penetrated. think actually XX% and health about you our China, less globally, revenue. it's is diagnostics of If

the care Chinese of less health revenue it's diagnostics in going than the So setting. and be is to XX%

Operator

from Our line next of the Doug comes from Cowen. question Schenkel

Your line is open.

Doug Schenkel

back in already? that guidance? recapturing you revenue China. like So go release soon? and do this slower-than-expected morning which visibility dynamic by there, let a recaptured are everybody. start Hey, in little how then you that can end treating for on question. for second Or QX to the to on I'd topic. markets? going the Have equipment you And budget detail capital we good revenue funding have you to in the me Could pause of provide investment more Thanks just taking

Marc Casper

Yes.

So thanks. Doug,

the XXX% terms driven release government entities. of In in funds, of controlled-type

the customers right? saw and government would certain of a in academic market in Chinese an industrial and government example owned by be of where we semiconductor they're an Chinese enterprises, that's fab customer. So certain parts industrial state-owned applied So the it and tech

during through is the be first of in immediately way would it terms or course that that that, the will In assumption we work timing the of didn't year, its the but assume low quarter guidance would guidance, way for is what China in for assumed is we've our double-digit the about assumed I is full we think it. year growth In what our China

Doug Schenkel

is the little I guidance. Okay, wanted unpack thank which to a bit you it's to for good a thing segue second more, that. And indeed

for the your revenue at long-term X% that initial of the outlined over you target Day to end X% first your X% is target organic growth on your of the year – the Analyst summer. So lower

and prepared of assumptions market this in missed one kind strong and strong is Thank XXXX what market little question, and share guess, just you after geography? remarks, I've I by year towards your to of a expect for And towards apologize just just a end layer growth lot a what terms beginning built just I guidance now, then of in while of of more you. end had trend in seemingly conservatism? are to this into could you Given terms Or couple but years? is if the conditions the revenue what you've growth you'd momentum element a mean this the of your really for normalizing in the

Marc Casper

takeaway. So thanks for to all, on take mean, guidance. about question of away going excited super if XXXX. you're is that I the first I'm the

them as thing, expect Fisher in the end put end the in three company. very those for strong XXXX me and XXXX, of let same relative been So good end strong share year to be performance of XXXX, markets gain XXXX, markets another and have Thermo performance we last very our well. to context. years, exactly The markets and

year, with long-term of the retired We're growth. the we're the that every in get So growth risk there's industry, line the organic X% with we some they risks materialize X% think level with year. consistent to world you you or the X% is about initiating to that because to raise expecting way it for be our through don't opportunity gives as quarter and go every and guidance those model

would and deliver XXXX. possible out aspiring to delivered, X% we to that higher the guidance reminder, starting in with said to our a that best X% as we were the range. about We posture the started I out feel is results. unfolds and that X% year move goal able here within X% be As great in we same. the We're range continue the do to the we to with always higher

hopefully, a you sense. So that gives

little the then details of growth of around that. on on a And bit the commentary some

single-digit You're going to high biotech with have pharma growth. and

academic, growth going – You're would digit is going the drivers where our mid-single-digit to and industrial the to markets see in give health and applied growth government will diagnostics, of single care from. end low come in you

Doug Schenkel

thanks Great, again.

Marc Casper

You’re welcome.

Operator

from line Evercore comes the question next Kumar of ISI. from Our Vijay

Your open. is line

Vijay Kumar

taking for guys, my Hey thanks question.

year. on below just what QX I'm Think commentary impact heard I'm here. below QX was I not the the days sure say drives the hundred there trend? on you couple points basis Just on any of that curious or guidance

Stephen Williamson

Vijay. Yes,

from of be comps that. the electron QX, to – then X the the one headwind it. that's less the under And microscopy. day driver yes, Those So really Analytical the business, point will from in selling Instruments particularly piece it's just

Vijay Kumar

big Got for you. it. question one Then Marc, picture

free Looking billion flow $X.X assumptions the here, cash cash. at

$X a Thermo share $X.X on from and be That's on shaping It's – a looking billion. unusual sort is how cash on perspective. funnel have an for billion is repo You burn up balance cash just of of Thermo. the for the sheet? thoughts plus the M&A existing, the year amount to but Any deployment been cap significant thoughts

Marc Casper

Yes.

for thanks question. the Vijay, So

year the back from the balance from beginning perspective, well looking goal the very the of of we the a last was from So capital set period played sheet forward, that. active before very strengthening then my looking and had deployment perspective, we finishing year out out of the which

of returned did some billion capital through refinancing. – And dividends. $X.X of terms and we as We to We the shareholders we and cash $X.X we buybacks M&A. So generated our deployed in flow. billion

strong a we year, have So as obviously this look balance to sheet. I very

amount significant a have of We capacity.

active know, We operate continue to fragmented a as M&A a we have very pipeline. very you industry. And in

pursue value. that create So look And we'll things shareholder and we plenty our strategy we aligned feel that things of only are at. with

unfolds. in capital, that our whatever $X.X as our whether best way the used, likely year on means Our it's convention M&A return that's year is on based combination of opportunity And make impacts deployment what's is basically is we'll – million or in the on we've just most return billion guidance the in assumption update which return the a And buybacks, buybacks $XXX about beyond unfolds, or dividends, or decisions numbers is we'll deploy then not the our that always EPS additional for two that. you EPS see which shareholders. we'll we as what to some and the of

Vijay Kumar

clarifying, Marc. Thanks for

Marc Casper

You’re welcome.

Operator

Our Wolfe line from next the comes from Stephen Beuchaw question of Research.

Your line is open.

Stephen Beuchaw

morning time good here. the for and thanks Hi,

it's the you around pharma a on broader whether do I then And simpler relative last First, and could have like, biopharma, hardware three prospectively, you it's research And saw I hardware two-parter. of component looks pharma how in to in a give then you in to years. specifically pharma, if XQ XXXX, in dynamics imagine bit sense just follow-up. bioprocess? wonder us how settings or the outlook research wanted purchasing growth in I and for drill two, year-end, for the maybe in much one a the

Marc Casper

fantastic for continuing the company, question. performance, pharma So, trend really for of fantastic the a I about Steve, the and biotech thanks When many the think years. year

entire across strength not the market We pharmaceutical the If year, year when biosciences, saw good good research For capital a a I safety we to services, the broad-based and deliberately, had in We across I something and equipment due the out, instruments quarter to the look portfolio. strength it's of and really in channel. in biotech was bioproduction, the had pharma at spending. And it's growth. performance, the double-digit portfolio. analytical it sense and left

there. growth So point. biotech in no guidance single-digit trajectory the for initial pharma with starting And starting a high we're as out change and

and growth last back expecting historically performance. high comfortable we're had the high go we portfolio. we few mid-single single-digit have feel starting So the in we strong single-digit started out And years, to over you based with the with on growth, if out momentum

about it. year-end spend So that's particular subsegment Nothing track capital, would think how I so don't I by much. on really

run. more out are a think across year-end normal the having usual, we was year playing that guidance some all business money I year, spend that which And averages out last in very our kind that the about of in with we portfolio. as of year-end line year-end strong but saw kind spends customers others, long and with had

strong XXXX below-average was As spends. a years in a two were reminder, the from I And spend. year-end year previous recollection, very think

so it our year guidance. in played out with – And last it varies, it but took line

Stephen Beuchaw

couple just of fine then And a appreciated. points. much Okay,

speak was about can relates And initiative follow-up to that How the normal look if could And it's how outlook, and up just trade Within at things broader to, again. XXXX year, that double-digit the over thinking given played XXXX you some level, a accelerated Thanks in play the hold say broader of it XXXX? to out increases to I we bioprocess, prior. then wonder into pricing. to year-on-year. at how as of pharma you're did to are out? we dynamics, safe the as price an in there growth course back then And going the corporate

Marc Casper

Yes.

the we On that couple of the had performed So will and I'll cover levels have bioprocess, take to little biologics have prior growth. companies north we to a strong very others pricing. reported and us, of continue then A perform there. Stephen

Stephen Williamson

year so in Yes. fact, X% as overall out the pricing, for expected year, in over we pricing And price offsetting, a tariffs. the had played of good

think as was going between XXXX. generally about of X.X% And really X% like that we So project forward, company's the kind – there. I goal price just in and the performance

Stephen Beuchaw

you. Thank

Marc Casper

for Operator, we have quick time one. one just

Operator

Okay.

Dan Our final come of line will question Arias from from the Stifel.

open. line is Your

Dan Arias

that Stephen, confirm point, impact But goes at over that think that. you just just margins follow that is overall to guys. Brammer, dilutive margins business the was some if from time? on you Thanks then accretive morning. up touch hoping on but also clarify the that of I there. to Good the Can timing I true. just on could on around just

Stephen Williamson

Yes.

company to for under it just the average full the XXXX. year margins, we on the Just expect be Brammer

be year. the getting decent the So up we'd the level it to at end of

So into that's think about pace. going right XXXX, at that

Dan Arias

a meaningful growth Okay. to Marc, over And guys, you I'm meant – then, year quantify like sure, but do, may just be it you hard last for so? think how the it's little or for gains share been to it's able are have what given seems you

Marc Casper

we'll for compare growth year. We we the – on next the to And had better terms in that's if or Yes. don't everybody our will – had share very of And expect have gain clarity X% of the We the have be we in relative good pieces reporting, obviously a the that X% we two. than growth. others, organic but that benefit solid when week performance.

year. strong another So

for So question. Dan, the thanks

Marc Casper

here. me it Let up wrap

So you. really pleased year. forward about another of deliver the on we opportunities XXXX. the of we're more much updating to the We're course excellent – sit you excited And first, thank what look But that ahead over us. course to

soon. Thermo So to you seeing thanks and of support Scientific, for Fisher forward look your

Operator

concludes you this participating. gentlemen, and call. Ladies for Thank today's conference

You now may disconnect.

Thermo Fisher Scientific (TMO) 30 Jan 202019 Q4 Earnings call transcript